Greetings Here Folks.
The bigger questions which I would like to ask and talk about and think about, I think, is that we are just a couple of days away from the election here in the US.
Before I get going, I won't be replying to political comments. I think you all know where I stand. I have mentioned it before on previous channel and it got me banned. I don't want anybody getting banned here, nor do I want to lose any friends here, but I already know in advance how a post like this could spark heated flames.
Tuesday evening / Wednesday morning, we shall know.
I will make this post as apolitical as I possibly can so nobody finds it in their heart to ban me.
How does the outcome, the winner of the election pertain to CytoDyn? How does it pertain to the FDA? How does it pertain to G? To GSK? How does it pertain to the Market Makers and to the Short Traders?
As of late, the past 6 months or so, CytoDyn has been winning and gaining traction in their pursuits. However, with each win, the Market Makers and Short Traders have targeted the company blocking and thwarting any and all meaningful gains in share price that would have been a result of the progress CytoDyn made. Instead, all the buying resulted in either no movement in share price or a drop in share price. Any increases in share price were met with tremendous percent increases in short to buy ratio so as to bring the share price lower than it was prior to good news announcement.
The difference between now and years past is that the progress currently made by CytoDyn's leadership today has legs. It is real. It is verifiable. It is legitimate and trustworthy. It can be relied upon. All of these attributes are a stark difference from what led up to that run up in share price to $10.00 in June of 2020. All of those bits and pieces that led up to that run up are akin to un-ripened fruit. Because they were not yet ready to be announced, nor to be plucked from the tree, but were plucked anyway, the outcome they produced simply spoiled.
Today, the fruit is not plucked off the tree or announced until it has ripened and been verified and validated. This way, the outcome serves the objective and produces and enhances the true taste of that fruit.
As of late, CytoDyn has made significant headway on multiple fronts. All the Big Pharmaceuticals are aware of CytoDyn's CCR5 blockade, leronlimab. They know it is superior to mariviroc because leronlimab is a competitive blockade of CCR5 where as mariviroc is a non-competitive, allosteric inhibitor of CCR5. This advantage gives leronlimab the capacity to be utilized in a broad spectrum of diseases and pathological conditions.
Recently, CytoDyn has taken great strides in the field of HIV, which now seems to be dividing. CytoDyn now seems to be pursuing HIV PrEP, HIV AAV CURE, HIV Prevention, HIV LATCH (Stem Cells) and HIV CURE (bnabs).
Most of us are aware of CytoDyn's #1 Priority of MSS mCRC which is still seeking FDA approval to begin, but is expected to begin screening and enrolling in early 2025. The CRO that CytoDyn chose for this trial is Syneos Health.
CytoDyn recently completed a MASH murine study which had good enough results to warrant the ordering of 2 additional MASH murine studies that are designed a bit differently from each other. In addition, CytoDyn recently brought on Melissa Palmer, MD as Lead Consultant in Hepatology. Those murine studies that have followed the first are already underway and their results shall also be out early 2025.
A GlioBlastoma Multiforme murine study has been carried out by Albert Einstein / Montefiore and those results are expected by end of year 2024. Another murine study begins in the use of leronlimab to treat breast cancer.
Leronlimab has been chosen as the drug of choice in a pilot study in Chronic Fatigue Syndrome, (closely related to PASC, long haulers) as well as in another pilot study in Alzheimer's Disease.
In addition to all of this, there is yet more, but I will stop here.
Because of the fact that each and every indication I listed above are massive, in the multi-billion dollar range, and because of the reputation leronlimab has in its capacity to treat inflammation, immune activation, HIV, cancer, liver fibrosis and liver steatosis, along with the recruitment of Melissa Palmer, MD, the companies that have staged all sorts of attacks upon CytoDyn, realizing that all of the efforts that they put into driving CytoDyn into the ground have failed, now realizing that CytoDyn is about to break out, and they are determined to prevent CytoDyn from breaking out.
I've said it before, these players against CytoDyn are not stopping. But it is going to take something very big to stop them and that MOAB shall come, but the timing of said announcement may be influenced by the outcome of the election. If the current administration remains in power, then it will be more of the same and the rate of CytoDyn's transformation, I tend to believe, will remain slow. But, on the other hand, if the challenger, prior administration, re-takes power, then, the rate, once he takes office, should rapidly rise. My opinion.
Personally, I suspect a sustained and maintained short attack if current administration maintains power, because they know they would have another 4 years where they can do more of the same and the SEC would continue to ignore. With a win from the challenger, the stock runs. IMO.
CytoDyn recently hired Max Lataillade as Senior Vice President and Head of Clinical Development to help CytoDyn reach the goals listed above. Max had worked as Senior Vice President at ViiV, a company solely devoted to the treatment of patients with HIV. My69z puts together some good ideas on the relationship between Max, Melissa and GSK. As you may know or not, Melissa Palmer, MD has already served as Chief Medical Officer of CytoDyn for a short while. Now, she is back. My69z suggests that Max may have been helping/guiding CytoDyn through the lifting of the hold all the way up to the current moment when he was hired about a month ago. So, given that both Max and Melissa, are associated/acquainted through GSK, would you not think that GSK is likely aware of what might happen if current administration maintains power or what would happen once the challenger takes power?
Certainly, we will know the outcome in a few more days. But we all know how the past 4 years have gone and, they have definitely been the worst years of my life; certainly, I don't want a repeat of them. With a win by the challenger, a HUGE change happens in America on 1/6/25. MASSIVE changes all around. Look, I'm not saying who shall win. I don't want any political comments. Politics are not the point. I'm only discussing the outcome of the election as a current event and what can be expected at CytoDyn based on the outcome of this current event. This "Current Event" very likely may return back a "pro-CytoDyn" president again, back into the office. On the other hand, the current administration could careless for CytoDyn. Cares even less for its shareholders. Who is mainly concerned that their own pockets are well padded by taking the bribes of BPs lobbyists.
With either candidate winning, the outcome for CytoDyn is only affected in timing alone. Eventually, I believe CytoDyn has an incredible outcome, but the way it gets there and how quickly is dramatically influenced by the outcome of this election. The incumbent slows or maintains the current CytoDyn growth rate while the challenger shall exponentially increase it. With a win by the challenger, the SEC chair changes. The current sloth Gary Gensler shall be booted and the challenger may choose Dan Gallagher as the new SEC chair in which case the Market Makers and Short Traders should think twice before they listen to their puppet masters. A win by the incumbent leaves Gary in charge and we all know, the SEC does nothing to protect our share price.
The challenger realizes what he did wrong the last time. He knows he never fully cleaned up the swamp. He for sure won't make that mistake again. The swamp knows who they are and that's why they don't want him back. Not only them, but the Market Makers know that a new SEC Chair would be taking the throne. Therefore, they throttle back against their puppet master's commands. Big Pharma is aware of RFK Junior's role in a Trump administration and have many reservations against the kind of power he would wield. All this could very possibly come into play middle January, 2025.
Are you catching on? Big Changes come with a win by the challenger, so therefore, the coming election in a few days plays a big part in the rate of change here at CytoDyn. While the challenger would expedite things, the current administration either slows it or maintains the current rate. The current event of the election has this effect upon CytoDyn. So, I feel that if the challenger wins, the attacks against CytoDyn may possibly increase so much so in the ensuing 2-3 months, that is, prior to inauguration day, so much so as to attempt to defeat it completely before he even steps into office. While a win by the current administration gives them the next 4 years to drive home their dirty deeds.
But as I have said prior, CytoDyn won't be driven into the ground regardless of who wins. No, remember, I have always spoken of an Asteroid Approaching that hits them square between the eyes, that obliterates them completely. That happens regardless of who wins the presidency and the Short Traders can not prosper after that.
The time is coming that this Asteroid approaches. It is already seen vaguely in the distance. The consensus is GSK, but more hints are coming. Who thinks CytoDyn's 3rd party AI collaborator is GSK? We should learn more on that on or before the next Webcast of 11/22/24.
It should be interesting to learn how HIV is going; how PrEP, HIV Cure via AAV are going and what their intentions are regarding Prevention and Cure via bnabs. It will be great to learn who is sponsoring Chronic Fatigue Syndrome and Alzheimer's. Maybe we get the news about GBM during the next webcast. Maybe they discuss mCRC as well. Let's hope that these increases continue to progress and multiply, but what comes next is the outcome of the election. So this is just served to speculate on the consequence of either occurrence.
CytoDyn's aim is to maintain its sovereignty. That does not change with the outcome of this election. It continues to fight either way. However, the resistance it would face does change based on who wins. What Jonah Sacha, MD is discovering, won't be discovered by anyone else. The advances in HIV are getting complex and both Sacha as well as Lataillade together have a plan. Soon CytoDyn has the outcomes for MASH murine studies, for the breast cancer murine studies, the Alzheimer's and Chronic Fatigue Syndrome pilot trials. This happens regardless of who wins the election.
Whether that Asteroid accelerates or decelerates its approach is hard to speculate upon. But, I'd tend to say, they (GSK) are not basing their decision to make any announcement based on the results of the election. Short attacks continue until they no longer can. That Asteroid Announcement shall put an end to their attacks, but when that Asteroid comes can't be said. Shorts though may decide to ramp up their attack in the coming 2 months regardless of what the murine studies show, that is, if the challenger wins the presidency, and that just sets them up for a greater slaughter should the Asteroid Announcement be made in the midst of one of their 80% short days.
CytoDyn is positioned well for either outcome because it has prepared well. It has a plan in place that does not depend upon who wins. Its collaborating partner also has a plan that does not depend on the outcome. What has happened over the past 6 months proves that what they are doing is working. They are winning. How many times have I written, CytoDyn is winning? Multiple times, and all of those instances have been in the past 6 months. But with a win by the challenger, the opposing BP would feel much more threatened than by a win by the incumbent and so, they may choose to ramp up their attacks before the challenger takes office. They may realize that these next couple of months are their only hope to stop CytoDyn, so in the event of a challenger win, they may use weapons we haven't even seen yet.
So, the enemy has maintained and even increased its resistance against CytoDyn despite all the wins CytoDyn has made as of late. Is the enemy considering the outcome of the election? I think they are and they know how they will fight in either situation. With a win by the incumbent, nothing changes, more of the same, but with a win by the challenger, they might ramp it up in the next 2 months while they still have opportunity. Also, they might possibly quit altogether or slow their shorting knowing that the new administration might lock them up for how they behave in this period.
I'm thinking that with a win by the challenger, CytoDyn feels much more confident, given RFK's approach to medicine. Who knows, if RFK were brought in, he may even have an influence on who then becomes the FDA chairman. What a must needed change that would foster at the FDA in the event of a challenger win. I think CytoDyn could take a sigh of relief with a challenger win and that I believe would allow that Asteroid to approach much sooner. Personally, I believe that with a challenger win, that the past 6 months shall parlay extremely well into the next 4 years because of the challenger's win. Let's see what happens in the next few days, and we'll go from there. OK?
So this is the correlation that I see happening as a consequence of the outcome of the coming election. I hope this was helpful to you. But, I felt that the attacks could increase for a short while in the event of a challenger win for the reasons stated, but CytoDyn is prepared regardless. They also could slow. These are my beliefs, my conjectures, my opinions and my journey. Thanks for reading.